Insulin delivery with FlexPen®: Dose accuracy, patient preference and adherence

Expert Opinion on Drug Delivery

Volumn 5, Issue 8, 2008, Pages 915-925

  Pfutzner A ^a   Asakura, T ^b   Sommavilla, B ^c   Lee, Wonchan C ^d  

^a Institute for Clinical Research and Development   (Germany)

^b NIIGATA UNIVERSITY OF PHARMACY AND APPLIED LIFE SCIENCES   (Japan)

^c Diabetes Education Center   (Austria)

^d Abt Bio Pharma Solutions Inc   (United States)

Author keywords

Dose accuracy; FlexPen; Insulin delivery; Patient preference

Indexed keywords

HEMOGLOBIN A1C; INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN LISPRO; LONG ACTING DRUG; NEUTRAL INSULIN; NOVOMIX 50; NOVOMIX 70; NOVOPEN 3; RECOMBINANT HUMAN INSULIN; SHORT ACTING DRUG; UNCLASSIFIED DRUG;

ACCURACY; ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; DOSE CALCULATION; DRUG COST; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG FORMULATION; DRUG MEGADOSE; DRUG PREFERENCE; DRUG SAFETY; ECONOMIC EVALUATION; EQUIPMENT DESIGN; GLYCEMIC CONTROL; HEALTH CARE COST; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; INSULIN TREATMENT; LOW DRUG DOSE; NEEDLE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT ATTITUDE; PATIENT COMPLIANCE; UNSPECIFIED SIDE EFFECT;

DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DISPOSABLE EQUIPMENT; DRUG DELIVERY SYSTEMS; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN; PATIENT COMPLIANCE; PATIENT SATISFACTION; SELF ADMINISTRATION; SYRINGES;

EID: 52049091038     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425247.5.8.915     Document Type: Article

References (59)

1. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352(9131):837-53
2. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329(14):977-86
3. Mollema ED, Snoek FJ, Ader HJ, et al. Insulin-treated diabetes patients with fear of self-injecting or fear of self-testing: psychological comorbidity and general well-being. J Psychosom Res 2001;51(5):665-72
4. Mollema ED, Snoek FJ, Heine RJ, Van Der Ploeg HM. Phobia of self-injecting and self-testing in insulin-treated diabetes patients: opportunities for screening. Diabet Med 2001;18(8):671-4
5. Zambanini A, Newson RB, Maisey M, Feher MD. Injection related anxiety in insulin-treated diabetes. Diabetes Res Clin Pract 1999;46(3):239-46
6. Hunt LM, Valenzuela MA, Pugh JA. NIDDM patients' fears and hopes about insulin therapy. The basis of patient reluctance. Diabetes Care 1997;20(3):292-8
7. Hamilton JG. Needle phobia: a neglected diagnosis. J Fam Pract 1995;41(2):169-75
8. Glasgow RE, Fisher EB, Anderson BJ, et al. Behavioral science in diabetes. Contributions and opportunities. Diabetes Care 1999;22(5):832-43
9. Peyrot M, Rubin RR, Lauritzen T, et al. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care 2005;28(11):2673-9
10. Peyrot M, Rubin RR, Lauritzen T, et al. Psychosocial problems and barriers to improved diabetes management: results of the Cross-National Diabetes Attitudes, Wishes and Needs (DAWN) Study. Diabet Med 2005;22(10):1379-85
11. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23(8):1296-310
12. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 2002;287(19):2563-9
13. De Sonnaville JJ, Bouma M, Colly LP, et al. Sustained good glycaemic control in NIDDM patients by implementation of structured care in general practice: 2-year follow-up study. Diabetologia 1997;40(11):1334-40
14. Clarke A, Spollett G. Dose accuracy and injection force dynamics of a novel disposable insulin pen. Expert Opin Drug Deliv 2007;4(2):165-74
15. Gnanalingham MG, Newland P, Smith CP. Accuracy and reproducibility of low dose insulin administration using pen-injectors and syringes. Arch Dis Child 1998;79(1):59-62
16. Keith K, Nicholson D, Rogers D. Accuracy and precision of low-dose insulin administration using syringes, pen injectors, and a pump. Clin Pediatr (Phila) 2004;43(1):69-74
17. Lteif AN, Schwenk WF. Accuracy of pen injectors versus insulin syringes in children with type 1 diabetes. Diabetes Care 1999;22(1): 137-40
18. Graff MR, McClanahan MA. Assessment by patients with diabetes mellitus of two insulin pen delivery systems versus a vial and syringe. Chin Ther 1998;20(3):486-96
19. Albano S. Assessment of quality of treatment in insulin-treated patients with diabetes using a pre-filled insulin pen. The ORBITER Study Group. Acta Biomed 2004;75(1):34-9
20. Lombardo F, Salzano G, Messina MF, De Luca F. Compliance and administration methods in management of type 1 diabetes. Acta Biomed 2005;76(Suppl 3):66-9
21. Summers KH, Szeinbach SL, Lenox SM. Preference for insulin delivery systems among current insulin users and nonusers. Clin Ther 2004;26(9):1498-505
22. Thurman JE. Insulin pen injection devices for management of patients with type 2 diabetes: considerations based on an endocrinologist's practical experience in the United States. Endocr Pract 2007;13(6):672-8
23. Rubin RR, Peyrot M. Quality of life, treatment satisfaction, and treatment preference associated with use of a pen device delivering a premixed 70/30 insulin aspart suspension (aspart protamine suspension/ soluble aspart) versus alternative treatment strategies. Diabetes Care 2004;27(10):2495-7
24. Stockl K, Ory C, Vanderplas A, et al. An evaluation of patient preference for an alternative insulin delivery system compared to standard vial and syringe. Curr Med Res Opin 2007;23(1):133-46
25. Lee WC, Balu S, Cobden D, et al. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data. Chin Ther 2006;28(10):1712-25; discussion 1710-1
26. IMS Health. Estimated number of patients using FlexPen®, based on worldwide sales in number of packs sold, IMS world wide data Q4'07 and Daily Defined Dosage (DDD) for insulin as issued by WHO; 2007
27. Niskanen L, Jensen LE, Rastam J, et al. Randomized, multinational, open-label, 2-period, crossover comparison of biphasic insulin aspart 30 and biphasic insulin lispro 25 and pen devices in adult patients with type 2 diabetes mellitus. Clin Ther 2004;26(4):531-40
28. Korytkowski M, Niskanen L, Asakura T. FlexPen: addressing issues of confidence and convenience in insulin delivery. Clin Ther 2005;27(Suppl B):S89-100
29. Hänel H, Weise A, Sun W, et al. Differences in the dose accuracy of insulin pens. J Diabetes Sci Tech 2008;2(3):478-81
30. Asakura T, Seino H, Kageyama M, Yohkoh N. Dosing accuracy of two insulin pre-filled pens. Curr Med Res Opin 2008;24(5):1429-34
31. Asakura T. Comparison of the dosing accuracy of two insulin injection devices. J Clin Res 2005;8:33-40
32. Asakura T, Seino H. Handling and safety of two insulin injection pens (FlexPen® and OptiClik®) in insulin-naive type 2 diabetes patients. Diabetes 2006;55(Suppl 1):A457
33. Asakura T, Seino H. Insulin dosing accuracy with FlexPen® versus syringe by healthcare professionals and healthy volunteers. Diabetes 2005;54(Suppl 1):A498-9
34. Coscelli C, Lostia S, Lunetta M, et al. Safety, efficacy, acceptability of a pre-filled insulin pen in diabetic patients over 60 years old. Diabetes Res Clin Pract 1995;28(3):173-7
35. Casella SJ, Mongilio MK, Plotnick LP, et al. Accuracy and precision of low-dose insulin administration. Pediatrics 1993;91(6):1155-7
36. Liebermeister H, Sammler A. Problems of the elderly, insulin injecting diabetic patients in ambulatory care. Versicherungsmedizin 1990;42(2):59-64
37. Korytkowski M, Bell D, Jacobsen C, Suwannasari R. A multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus. Clin Ther 2003;25(11):2836-48
38. Dreyer M. Comparison of metabolic control, safety, handling and patient acceptance of FlexPen with NovoLet in type 1 and type 2 diabetes patients. J Clin Res 2005;8:1-7
39. Asakura T, Seino H. A comparison of the usability of two types of disposable pen (FlexPen versus Humalog Kit) containing rapid-acting insulin analogues. Diabetes Metab 2003;29:S236
40. Lawton SA, Berg B. Comparative evaluation of FlexPen, a new prefilled insulin delivery system, among patients and healthcare professionals. Diabetes 2001;50(Suppl 2):A440
41. Haak T, Edelman S, Walter C, et al. Comparison of usability and patient preference for the new disposable insulin device Solostar versus Flexpen, lilly disposable pen, and a prototype pen: an open-label study. Clin Ther 2007;29(4):650-60
42. Pfutzner A, Reimer T, Frokjaer LPF, Jorgensen C. Prefilled insulin device with reduced injection force: patient perception and accuracy. Curt Med Res Opin 2008;24(9):2545-9. Published online on 29 July 2008; doi:10.1185/03007990802329264
43. Rissler J, Rissler J, Jorgensen C, Rye Hansen M, Hansen N-A. Evaluation of injection force dynamics of a modified prefilled insulin pen. Expert Opin Pharmacother 2008;9(13):2217-22
44. Sommavilla B, Jorgensen C, Jensen KH. Safety, simplicity and convenience of a modified prefilled insulin pen. Expert Opin Pharmacother 2008;9(13):2223-32
45. Pawaskar MD, Camacho FT, Anderson RT, et al. Health care costs and medication adherence associated with initiation of insulin pen therapy in medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis. Clin Ther 2007;29(Spec No):1294-305
46. Alvarez Guisasola F, Tofe Povedano S, Krishnarajah G, et al. Hypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal in patients with type 2 diabetes mellitus: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) Study. Diabetes Obes Metab 2008;1O(Suppl 1):25-32
47. Cramer JA, Pugh MJ. The influence of insulin use on glycemic control: how well do adults follow prescriptions for insulin? Diabetes Care 2005;28(1):78-83
48. Morris AD, Boyle DI, McMahon AD, et al. Adherence to insulin treatment, glycaemic control, and ketoacidosis in insulin-dependent diabetes mellitus. The DARTS/MEMO Collaboration. Diabetes Audit and Research in Tayside Scotland. Medicines Monitoring Unit. Lancet 1997;350(9090):1505-10
49. Donnelly LA, Morris AD, Evans JM. Adherence to insulin and its association with glycaemic control in patients with type 2 diabetes. QJM 2007;100(6):345-50
50. Kadiri A, Chraibi A, Marouan F, et al. Comparison of NovoPen 3 and syringes/vials in the acceptance of insulin therapy in NIDDM patients with secondary failure to oral Hypoglycaemic agents. Diabetes Res Clin Pract 1998;41(1):15-23
51. Egekvist H, Bjerring P, Arendt-Nielsen L. Pain and mechanical injury of human skin following needle insertions. Eur J Pain 1999;3(1):41-9
52. Savas S, Koroglu BK, Koyuncuoglu HR, et al. The effects of the diabetes related soft tissue hand lesions and the reduced hand strength on functional disability of hand in type 2 diabetic patients. Diabetes Res Clin Pract 2007;77(1):77-83
53. Schady W, Abuaisha B, Boulton AJ. Observations on severe ulnar neuropathy in diabetes. J Diabetes Complications 1998;12(3):128-32
54. Ziegler D, Gries FA, Spuler M, Lessmann F. The epidemiology of diabetic neuropathy. DiaCAN Multicenter Study Group. Diabet Med 1993;10(Suppl 2):82S-86S
55. Bohannon NJ, Ohannesian JP, Burdan AL, et al. Patient and physician satisfaction with the Humulin/Humalog Pen, a new 3.0-mL prefilled pen device for insulin delivery. Clin Ther 2000;22(9): 1049-67
56. Lee JM, Botteman MF, Nicklasson L, et al. Needlestick injury in acute care nurses caring for patients with diabetes mellitus: a retrospective study. Curt Med Res Opin 2005;21(5):741-7
57. Khafagy ELS, Morishita M, Onuki Y, Takayama K. Current challenges in non-invasive insulin delivery systems: a comparative review. Adv Drug Deliv Rev 2007;59(15):1521-46
58. Lassmann-Vague V, Raccah D. Alternatives routes of insulin delivery. Diabetes Metab 2006;32(5 Pt 2):513-22
59. Pickup JC, Renard E. Long-acting insulin analogs versus insulin pump therapy for the treatment of type 1 and type 2 diabetes. Diabetes Care 2008;31(Suppl 2):S140-5